| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neurology, School of Medicine, University of California, San Francisco, CA.
We investigated the effectiveness of botulinum toxin in 17 patients with limb dystonias (10 with occupational cramps, three with idiopathic dystonia unrelated to activity, and two each with post-stroke and parkinsonian dystonia) in a placebo-controlled, blinded study. We identified affected muscles clinically and by recording the EMG from implanted wire electrodes at rest and during performance of tasks that precipitated abnormal postures. There were three injections given with graded doses of toxin (average doses, 5 to 10, 10 to 20, and 20 to 40 units per muscle) and one with placebo, in random order. Subjective improvement occurred after 53% of injections of botulinum toxin, and this was substantial in 24%. Only one patient (7%) improved after placebo injection. Subjective improvement occurred in 82% of patients with at least one dose of toxin, lasting for 1 to 4 months. Response rates were similar between clinical groups. Objective evaluation failed to demonstrate significant improvement following treatment with toxin compared with placebo. The major side effect was transient focal weakness after 53% of injections of toxin.
Address correspondence and reprint requests to Dr. Michael J. Aminoff, Room 794-M, Box 0114, School of Medicine, University of California, San Francisco, CA 94143–0114.
Received June 28, 1991. Accepted for publication in final form August 21, 1991.
This article has been cited by other articles:
|
|
 |
|
  D. M. Simpson, A. Blitzer, A. Brashear, C. Comella, R. Dubinsky, M. Hallett, J. Jankovic, B. Karp, C. L. Ludlow, J. M. Miyasaki, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, May 6, 2008; 70(19): 1699 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J M Kruisdijk, J H T M Koelman, B W Ongerboer de Visser, R J de Haan, and J D Speelman Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up J. Neurol. Neurosurg. Psychiatry, March 1, 2007; 78(3): 264 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T Lin, E. A Shamim, and M. Hallett Focal hand dystonia Practical Neurology, October 1, 2006; 6(5): 278 - 287. [Full Text] [PDF]
|
|
|
|
|
|
R Djebbari, S T du Montcel, S Sangla, J S Vidal, G Gallouedec, and M Vidailhet Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin J. Neurol. Neurosurg. Psychiatry, December 1, 2004; 75(12): 1688 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Hyman, M Barnes, B Bhakta, A Cozens, M Bakheit, B Kreczy-Kleedorfer, W Poewe, J Wissel, P Bain, S Glickman, et al. Botulinum toxin (Dysport(R)) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 707 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bakheit, D. McLellan, and M. Burnett Symptomatic and functional improvement of foot dystonia with medial popliteal nerve block Clinical Rehabilitation, November 1, 1996; 10(4): 347 - 349. [PDF]
|
|
|
|
|
|
D. Skeil and M. Barnes The local treatment of spasticity Clinical Rehabilitation, August 1, 1994; 8(3): 240 - 246. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
